DK1755664T3 - Vacciner med prrsv-underenhed - Google Patents
Vacciner med prrsv-underenhed Download PDFInfo
- Publication number
- DK1755664T3 DK1755664T3 DK05766550.7T DK05766550T DK1755664T3 DK 1755664 T3 DK1755664 T3 DK 1755664T3 DK 05766550 T DK05766550 T DK 05766550T DK 1755664 T3 DK1755664 T3 DK 1755664T3
- Authority
- DK
- Denmark
- Prior art keywords
- prrsv
- dna
- orf1
- group
- sequence
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 43
- 239000002773 nucleotide Substances 0.000 claims description 42
- 101000833492 Homo sapiens Jouberin Proteins 0.000 claims description 32
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 claims description 32
- 102100024407 Jouberin Human genes 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 30
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 33
- 102000053602 DNA Human genes 0.000 description 33
- 241000282887 Suidae Species 0.000 description 25
- 108700026244 Open Reading Frames Proteins 0.000 description 24
- 238000000034 method Methods 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 108010041986 DNA Vaccines Proteins 0.000 description 14
- 229940021995 DNA vaccine Drugs 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 4
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 4
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 4
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 4
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 4
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 4
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 4
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 4
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 4
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 4
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 4
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 4
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 4
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 4
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 4
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 229940065638 intron a Drugs 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 101150039660 HA gene Proteins 0.000 description 3
- 101150001779 ORF1a gene Proteins 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 2
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 2
- 229940022005 RNA vaccine Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- -1 nucleoside triphosphates Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 1
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 1
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 1
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 1
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241001673669 Porcine circovirus 2 Species 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 1
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 1
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Vaccine, som er i stand til at inducere et immunrespons mod PRRSV omfattende: en første del af PRRSV-ORF1-DNA, hvor delen er valgt fra gruppen bestående af SEQ ID Nos. 2-6, 9 og kombinationer deraf; og et farmakologisk bærestof.
2. Vaccine ifølge krav 1, yderligere omfattende en anden del af DNA fra PRRSV valgt fra gruppen bestående af mindst 21 tilstødende nukleotider fra en PRRSV ORF forskellig fra ORF1, mindst 21 tilstødende nukleotider fra PRRSV-ORF1 og kombinationer deraf.
3. Vaccine ifølge krav 1, yderligere omfattende en bestanddel valgt fra gruppen bestående af adjuvanser, excipienser og kombinationer deraf.
4. Anvendelse af en første del af PRRSV-ORF1-DNA, hvor delen er valgt fra gruppen bestående af SEQ ID Nos. 2-6, 9 og kombinationer deraf, til fremstilling af en sammensætning for at inducere et immunrespons mod PRRSV i et dyr, som er modtagelig for PRRSV-infektion, hvor sammensætningen er til indgivelse til dyret.
5. Anvendelse ifølge krav 4, hvor en anden indgivelse af sammensætningen er tilvejebragt.
6. Anvendelse ifølge krav 5, hvor sammensætningen yderligere omfatter en anden DNA-del valgt fra gruppen bestående af mindst 21 tilstødende nukleotider fra en PRRSV-ORF forskellig fra ORF1, mindst 21 tilstødende nukleotider fra ORF1 og kombinationer deraf.
7. Anvendelse ifølge krav 5, hvor sammensætningen yderligere omfatter en ingrediens valgt fra gruppen bestående af adjuvanser, excipienser og kombinationer deraf.
8. Vektor omfattende mindst en del af PRRSV-ORF1-DNA, hvor delen er valgt fra gruppen bestående af SEQ ID Nos. 2-6, 9 og kombinationer deraf.
9. Vektoren ifølge krav 8, hvor vektoren er et plasmid.
10. Vektoren ifølge krav 8, hvor vektoren yderligere omfatter en anden del af PRRSV-DNA valgt fra gruppen bestående af mindst 21 tilstødende nukleotider fra en PRRSV-ORF forskellig fra ORF1, mindst 21 tilstødende nukleotider fra ORF1 og kombinationer deraf.
11. Celle indeholdende et plasmid ifølge krav 9.
12. Celle ifølge krav 11, hvor plasmidet yderligere omfatter en anden del af PRRSV-DNA valgt fra gruppen bestående af mindst 21 tilstødende nukleotider fra et PRRSV-ORF forskellig fra ORF1, mindst 21 tilstødende nukleotider fra ORF1 og kombinationer deraf.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58135004P | 2004-06-17 | 2004-06-17 | |
US11/154,617 US7722878B2 (en) | 2004-06-17 | 2005-06-16 | PRRSV subunit vaccines |
PCT/US2005/021973 WO2006002193A2 (en) | 2004-06-17 | 2005-06-17 | Prrsv subunit vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1755664T3 true DK1755664T3 (da) | 2015-08-24 |
Family
ID=35431312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05766550.7T DK1755664T3 (da) | 2004-06-17 | 2005-06-17 | Vacciner med prrsv-underenhed |
Country Status (14)
Country | Link |
---|---|
US (1) | US7722878B2 (da) |
EP (1) | EP1755664B1 (da) |
JP (1) | JP2008503221A (da) |
KR (1) | KR20070028431A (da) |
AR (1) | AR049825A1 (da) |
AU (1) | AU2005258092A1 (da) |
BR (1) | BRPI0510930A (da) |
CA (1) | CA2570778A1 (da) |
DK (1) | DK1755664T3 (da) |
ES (1) | ES2546933T3 (da) |
MX (1) | MXPA06014821A (da) |
RU (1) | RU2007101531A (da) |
TW (1) | TW200603825A (da) |
WO (1) | WO2006002193A2 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
WO2000053787A1 (en) | 1999-03-08 | 2000-09-14 | Id-Lelystad, Instituut Voor Dierhouderij En Dierg Ezondheid B.V. | Prrsv vaccines |
CA2650236C (en) | 1999-04-22 | 2016-01-12 | United States Of America, As Represented By The Secretary Of Agriculture | Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
TW200604526A (en) | 2004-06-18 | 2006-02-01 | Unviersity Of Minnesota | Identifying virally infected and vaccinated organisms |
US7632636B2 (en) | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
WO2007002321A2 (en) | 2005-06-24 | 2007-01-04 | Regents Of The University Of Minnesota | Prrs viruses, infectious clones, mutants thereof, and methods of use |
US8436337B2 (en) * | 2009-05-12 | 2013-05-07 | The State of Oregon Acting By and Through The State Board of Higher Education on Behalf of Oregon State Unitiversity | Amorphous multi-component metallic thin films for electronic devices |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
EA038012B1 (ru) | 2011-02-17 | 2021-06-23 | Бёрингер Ингельхайм Ветмедика Гмбх | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса |
CA2827337C (en) | 2011-02-17 | 2019-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Commercial scale process for production of prrsv |
WO2012129176A1 (en) * | 2011-03-18 | 2012-09-27 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Amorphous multi-component metal/metal oxide nanolaminate metamaterials and devices based thereon |
WO2012153160A1 (es) | 2011-05-07 | 2012-11-15 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra prrs en vector viral |
US9187731B2 (en) * | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
WO2013017568A1 (en) | 2011-07-29 | 2013-02-07 | Boehringer Ingelheim Vetmedica Gmbh | INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF |
CN105264618B (zh) | 2012-11-12 | 2018-06-05 | 俄勒冈州立大学 | 非晶金属薄膜非线性电阻器 |
WO2014150822A2 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
ES2940691T3 (es) | 2013-12-20 | 2023-05-10 | Boehringer Ingelheim Vetmedica Gmbh | Variante de virus PRRS, clon de ADNc de virus PRRS europeo y usos de los mismos |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6773908B1 (en) * | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
US6592873B1 (en) * | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
US20020012670A1 (en) * | 2000-01-26 | 2002-01-31 | Knut Elbers | Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV) |
US6841364B2 (en) * | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
-
2005
- 2005-06-16 US US11/154,617 patent/US7722878B2/en active Active
- 2005-06-17 DK DK05766550.7T patent/DK1755664T3/da active
- 2005-06-17 BR BRPI0510930-2A patent/BRPI0510930A/pt not_active Application Discontinuation
- 2005-06-17 AU AU2005258092A patent/AU2005258092A1/en not_active Abandoned
- 2005-06-17 EP EP05766550.7A patent/EP1755664B1/en active Active
- 2005-06-17 JP JP2007516840A patent/JP2008503221A/ja not_active Withdrawn
- 2005-06-17 KR KR1020067026720A patent/KR20070028431A/ko not_active Application Discontinuation
- 2005-06-17 WO PCT/US2005/021973 patent/WO2006002193A2/en active Application Filing
- 2005-06-17 MX MXPA06014821A patent/MXPA06014821A/es not_active Application Discontinuation
- 2005-06-17 CA CA002570778A patent/CA2570778A1/en not_active Abandoned
- 2005-06-17 ES ES05766550.7T patent/ES2546933T3/es active Active
- 2005-06-17 AR ARP050102515A patent/AR049825A1/es active Pending
- 2005-06-17 RU RU2007101531/13A patent/RU2007101531A/ru unknown
- 2005-06-17 TW TW094120169A patent/TW200603825A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006002193A2 (en) | 2006-01-05 |
AU2005258092A1 (en) | 2006-01-05 |
TW200603825A (en) | 2006-02-01 |
EP1755664B1 (en) | 2015-06-10 |
AR049825A1 (es) | 2006-09-06 |
EP1755664A2 (en) | 2007-02-28 |
US7722878B2 (en) | 2010-05-25 |
KR20070028431A (ko) | 2007-03-12 |
ES2546933T3 (es) | 2015-09-30 |
US20080038293A1 (en) | 2008-02-14 |
JP2008503221A (ja) | 2008-02-07 |
WO2006002193A3 (en) | 2006-03-02 |
RU2007101531A (ru) | 2008-07-27 |
MXPA06014821A (es) | 2007-03-26 |
CA2570778A1 (en) | 2006-01-05 |
BRPI0510930A (pt) | 2007-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1755664T3 (da) | Vacciner med prrsv-underenhed | |
KR20210092762A (ko) | 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물 | |
KR102012109B1 (ko) | 이유 전 돼지 생식기 호흡기 증후군(prrs) 바이러스에 대한 효과적인 백신접종 | |
AU2009285843B2 (en) | Vaccine against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS) | |
Kwang et al. | Antibody and cellular immune responses of swine following immunisation with plasmid DNA encoding the PRRS virus ORF’s 4, 5, 6 and 7 | |
KR100996105B1 (ko) | 돼지 생식기 호흡기 증후군 바이러스의 n 단백질돌연변이체 | |
KR102664662B1 (ko) | 돼지 파보바이러스 및 돼지 생식기 및 호흡기 증후군 바이러스에 대한 백신 및 이의 제조 방법 | |
US9579373B2 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
KR102602018B1 (ko) | 젖떼기 전, 유럽의 돼지 생식기 및 호흡기 증후군 (prrs) 균주 바이러스에 대한 효과적인 백신접종 | |
AU2019203817B2 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
WO2023056335A1 (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
CN114315985A (zh) | 减毒猪流行性腹泻病毒 | |
WO2024155943A2 (en) | Immunogenic compositions for african swine fever virus |